MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Beam Therapeutics Inc

Abrir

SetorSaúde

19.83 0.81

Visão Geral

Variação de preço das ações

24h

Atual

Mín

19.3

Máximo

20.16

Indicadores-chave

By Trading Economics

Rendimento

6.3M

-90M

Vendas

16M

30M

EPS

-1.09

Margem de lucro

-300.509

Funcionários

483

EBITDA

16M

-85M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+128.13% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-715M

1.8B

Abertura anterior

19.02

Fecho anterior

19.83

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bullish Evidence

Beam Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de set. de 2024, 14:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Comparação entre Pares

Variação de preço

Beam Therapeutics Inc Previsão

Preço-alvo

By TipRanks

128.13% parte superior

Previsão para 12 meses

Média 45.33 USD  128.13%

Máximo 80 USD

Mínimo 20 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Beam Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

12

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

16.98 / 20.809Suporte e Resistência

Curto Prazo

Very Strong Bullish Evidence

Médio Prazo

Very Strong Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.